{"abstract": "The deal would be the latest by a pharmaceutical company in what has been a record year for mergers and acquisitions, driven in part by transactions in the health care sector.", "web_url": "https://www.nytimes.com/2015/12/18/business/dealbook/astrazeneca-to-acquire-majority-stake-in-acerta-pharma.html", "snippet": "The deal would be the latest by a pharmaceutical company in what has been a record year for mergers and acquisitions, driven in part by transactions in the health care sector.", "lead_paragraph": "LONDON \u2014 The British drug maker AstraZeneca said on Thursday that it had agreed to acquire a majority stake in Acerta Pharma, a privately-held cancer drug developer with operations in the Netherlands and in California, for $4 billion.", "print_section": "B", "print_page": "5", "source": "The New York Times", "multimedia": [{"rank": 0, "subtype": "xlarge", "caption": null, "credit": null, "type": "image", "url": "images/2015/12/18/world/18db-Astrazeneca-web/18db-Astrazeneca-web-articleLarge.jpg", "height": 376, "width": 600, "subType": "xlarge", "crop_name": "articleLarge", "legacy": {"xlarge": "images/2015/12/18/world/18db-Astrazeneca-web/18db-Astrazeneca-web-articleLarge.jpg", "xlargewidth": 600, "xlargeheight": 376}}, {"rank": 0, "subtype": "jumbo", "caption": null, "credit": null, "type": "image", "url": "images/2015/12/18/world/18db-Astrazeneca-web/18db-Astrazeneca-web-jumbo.jpg", "height": 642, "width": 1024, "subType": "jumbo", "crop_name": "jumbo", "legacy": {}}, {"rank": 0, "subtype": "superJumbo", "caption": null, "credit": null, "type": "image", "url": "images/2015/12/18/world/18db-Astrazeneca-web/18db-Astrazeneca-web-superJumbo.jpg", "height": 1283, "width": 2048, "subType": "superJumbo", "crop_name": "superJumbo", "legacy": {}}, {"rank": 0, "subtype": "thumbnail", "caption": null, "credit": null, "type": "image", "url": "images/2015/12/18/world/18db-Astrazeneca-web/18db-Astrazeneca-web-thumbStandard.jpg", "height": 75, "width": 75, "subType": "thumbnail", "crop_name": "thumbStandard", "legacy": {"thumbnail": "images/2015/12/18/world/18db-Astrazeneca-web/18db-Astrazeneca-web-thumbStandard.jpg", "thumbnailwidth": 75, "thumbnailheight": 75}}, {"rank": 0, "subtype": "thumbLarge", "caption": null, "credit": null, "type": "image", "url": "images/2015/12/18/world/18db-Astrazeneca-web/18db-Astrazeneca-web-thumbLarge.jpg", "height": 150, "width": 150, "subType": "thumbLarge", "crop_name": "thumbLarge", "legacy": {}}], "headline": {"main": "AstraZeneca to Acquire Majority Stake in Acerta Pharma", "kicker": null, "content_kicker": null, "print_headline": "AstraZeneca to Acquire Control of a Cancer Drug Developer", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "organizations", "value": "Acerta Pharma BV", "rank": 1, "major": "N"}, {"name": "persons", "value": "Bray, Chad", "rank": 2, "major": "N"}, {"name": "organizations", "value": "AstraZeneca PLC", "rank": 3, "major": "N"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "rank": 4, "major": "N"}, {"name": "organizations", "value": "Pfizer Inc", "rank": 5, "major": "N"}, {"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "rank": 6, "major": "N"}, {"name": "glocations", "value": "Great Britain", "rank": 7, "major": "N"}], "pub_date": "2015-12-17T09:37:53+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "subsection_name": "DealBook", "byline": {"original": "By Chad Bray", "person": [{"firstname": "Chad", "middlename": null, "lastname": "Bray", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/abafa742-a66a-5faf-87c6-4b36c0e7c7c7", "word_count": 393, "uri": "nyt://article/abafa742-a66a-5faf-87c6-4b36c0e7c7c7"}